THALES
18.2.2021 16:56:12 CET | Business Wire | Press release
Thales has been chosen by the French defence procurement agency (DGA) to lead a second part of the ground segment of the Syracuse IV satellite communications system for the French armed forces. The Group was selected to supply the satellites in 2015 and to lead the first increment of the ground segment in 2019. This second capacity increment will enhance the interoperable communications capabilities of the French Army, Navy and Air Force in terms of data rate, availability, threat resistance and end-to-end connectivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210218005759/en/
Military satellite communications are more critical than ever and more vulnerable to attack; they are at the heart of the battle for strategic independence across all areas of military invention. Maintaining connectivity is key to the armed forces' ability to share information of all types between command centres and units deployed on any type of mission, including coalition operations.
This crucial programme milestone will enhance the performance of the ground segment across all theatres of operation for the three branches of the French military. The Thales solution will decisive in meeting the capacity requirements of land, naval and air force programmes such as Scorpion, FREMM, FDI, Barracuda, aircraft carrier, or Rafale. It aims to increase tenfold the secure communication capabilities of fighting vehicles on the move, surface vessels, submarines, and now also aircrafts. The Thales technology guarantees roaming communications in both X- and Ka-band and fully exploits the multi-spot potential of High Throughput Satellite (HTS) technology.
All the ground terminals in the system will be able to make optimum use of the Syracuse IV constellation. Their full interconnection via new docking terminals will allow considerable increase in data rate by ensuring joint cooperation in theatres of operations and with command centres. They will also be compatible with third-party satellite resources, depending on the area of deployment, without compromising communications security.
To achieve this objective, Thales will leverage its high-level systems integration expertise, and in particular its highly secure Modem 21 transmission system, to guarantee the availability and confidentiality of all communications and provide protection from the full spectrum of threats with no impact on operational performance, which is key to retaining information superiority in high-intensity combat. Thales’s NATO-standard Modem 21 solution has been proven in combat for over ten years.
The role of Thales Alenia Space in this contract will include mission management for the Syracuse constellation and management of the anchoring capabilities of the operator, the French Defence Ministry's joint infrastructure networks and information systems agency (DIRISI). Thales Alenia Space is also lead contractor for the contract notified by the DGA at the end of 2015 for the supply of the space segment consisting of the Syracuse 4A and 4B satellites and their control and mission ground segment.
Building on its expertise as a technology orchestrator and integrator for satellite communication systems in France and internationally, Thales has deployed over 1,000 secure, protected satcom stations worldwide, working with local industrial partners.
“As prime contractor for the Syracuse III and Syracuse IV ground segments since 2004, Thales is proud to strengthen its partnership with the French Ministry for the Armed Forces to help maintain the informational superiority of the country’s armed forces in highly contested environments. The sovereign satcom solutions to be supplied under this contract are resilient to all types of threats, combat-proven, and fully interoperable with the systems deployed by NATO coalition forces.” Marc Darmon, Executive Vice President, Secure Communications and Information Systems, Thales.
Note to editors
Syracuse is a series of protected telecommunication satellites designed to ensure that the French armed forces can communicate at all times between mainland France and units deployed around the world. The Syracuse programme provides a fully independent solution to France’s wide-ranging requirements for long-range, secure communication capabilities that are protected against electronic warfare threats. Three generations of Syracuse satellites were deployed between 1984 and 2015. The Syracuse IV programme will replace the Syracuse 3A and Syracuse 3B satellites currently in orbit, while delivering an expanded and upgraded network of ground stations. A constellation of two satellites has been ordered under the first phase of the Syracuse IV programme. They will be built by Thales Alenia Space and Airbus Defence and Space. The first satellite will enter service in 2022.
About Thales
Thales (Euronext Paris: HO) is a global high technology leader investing in digital and “deep tech” innovations –connectivity, big data, artificial intelligence, cybersecurity and quantum technology – to build a future we can all trust, which is vital to the development of our societies. The company provides solutions, services and products that help its customers – businesses, organisations and states – in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.
With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a basis including Gemalto over 12 months).
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005759/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
